Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851917)
Watch
English
Trastuzumab emtansine for HER2-positive advanced breast cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
23020162
retrieved
13 November 2016
title
Trastuzumab emtansine for HER2-positive advanced breast cancer
(English)
1 reference
stated in
PubMed
PubMed ID
23020162
retrieved
13 November 2016
main subject
ado-trastuzumab emtansine
0 references
Her2-receptor positive breast cancer
0 references
trastuzumab
1 reference
based on heuristic
inferred from title
author
Luca Gianni
series ordinal
3
object named as
Luca Gianni
0 references
author name string
Sunil Verma
series ordinal
1
0 references
David Miles
series ordinal
2
0 references
Ian E Krop
series ordinal
4
0 references
Manfred Welslau
series ordinal
5
0 references
José Baselga
series ordinal
6
0 references
Mark Pegram
series ordinal
7
0 references
Do-Youn Oh
series ordinal
8
0 references
Véronique Diéras
series ordinal
9
0 references
Ellie Guardino
series ordinal
10
0 references
Liang Fang
series ordinal
11
0 references
Michael W Lu
series ordinal
12
0 references
Steven Olsen
series ordinal
13
0 references
Kim Blackwell
series ordinal
14
0 references
language of work or name
English
0 references
publication date
8 November 2012
0 references
published in
The New England Journal of Medicine
0 references
volume
367
0 references
page(s)
1783-91
0 references
issue
19
0 references
cites work
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
20 March 2017
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
20 March 2017
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
20 March 2017
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
20 March 2017
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
20 March 2017
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
29 September 2017
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
29 September 2017
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
29 September 2017
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
29 September 2017
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
29 September 2017
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
29 September 2017
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5125250
retrieved
2 June 2018
Identifiers
DOI
10.1056/NEJMOA1209124
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
270177
OpenCitations bibliographic resource ID
270177
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
270177
PMCID
5125250
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
270177
PubMed ID
23020162
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
270177
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
